Tag Archives: DCPH

Deciphera Pharmaceuticals (DCPH) Received its Third Buy in a Row

After JMP Securities and Guggenheim gave Deciphera Pharmaceuticals (NASDAQ: DCPH) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Deciphera Pharmaceuticals today and set a price

Deciphera Pharmaceuticals Inc (DCPH) Has a New Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein initiated coverage with a Buy rating on Deciphera Pharmaceuticals Inc (DCPH – Research Report) today and set a price target of $60.00. The company’s shares closed last Monday at $34.15. According to TipRanks.com, Fein ‘s

Deciphera Pharmaceuticals Inc (DCPH) Received its Third Buy in a Row

After Deutsche Bank and J.P. Morgan gave Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) a Buy rating last month, the company received another Buy, this time from Nomura. Analyst Christopher Marai maintained a Buy rating on Deciphera Pharmaceuticals Inc yesterday and set

Deciphera Pharmaceuticals Inc (DCPH) Gets a Buy Rating from JonesTrading

In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Deciphera Pharmaceuticals Inc (DCPH – Research Report). The company’s shares closed last Monday at $38.25. Roy wrote: “Median PFS in 2L GIST at approx. 10 months

JonesTrading Thinks Deciphera Pharmaceuticals Inc’s Stock is Going to Recover

JonesTrading analyst Soumit Roy maintained a Buy rating on Deciphera Pharmaceuticals Inc (DCPH – Research Report) on May 10 and set a price target of $65. The company’s shares closed on Friday at $23.01, close to its 52-week low of

Deciphera Pharmaceuticals Inc (DCPH) Receives a Buy from Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Deciphera Pharmaceuticals Inc (DCPH – Research Report) today and set a price target of $53. The company’s shares closed yesterday at $22.31, close to its 52-week low of $18.40. Duncan